Trials / Terminated
TerminatedNCT02282358
Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
An Open-Label Phase II Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to learn if the study drug mocetinostat can slow the progression of cancer in people who have a mutation in CREBBP or EP300 in the genetic makeup of their cancer. The potential side effects of mocetinostat will also be studied.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mocetinostat |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2023-05-26
- Completion
- 2023-05-26
- First posted
- 2014-11-04
- Last updated
- 2024-03-08
- Results posted
- 2024-03-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02282358. Inclusion in this directory is not an endorsement.